It was found that ST could block the inward and outward currents of Kir2.1, and it was the first traditional Chinese medicine to block Kir2.1 and its mutants, which might become a targeted drug for type 3 short QT syndrome (sqt3). This evidence concerns the gene KCNJ2 and short QT syndrome type 3.